Boxin Biotechnology

Boxin Biotechnology is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on the discovery and development of innovative nanobody-based therapeutics. The company utilizes its proprietary nanobody platform to engineer multi-specific biologics with enhanced tissue penetration and stability compared to traditional antibodies. Boxin's primary therapeutic focus areas include ophthalmology and oncology, with a pipeline led by BX001, a bispecific nanobody targeting VEGF and ANG2 for retinal diseases. By leveraging the unique structural properties of single-domain antibodies, the company aims to provide more effective and convenient treatment options for patients with chronic conditions.